Bias within economic evaluations – the impact of considering the future entry of lower-cost generics on currently estimated incremental cost-effectiveness ratios of a new drug

Jason R Guertin1 CHUM Research Center, Montréal, QC, Canada;2 Programs for Assessment of Health Technology in Health Research Institute, Hamilton, ON, Canada

Dominic Mitchell1 CHUM Research Center, Montréal, QC, Canada;3 Logimétrix Inc., Repentigny, QC, Canada

Farzad Ali4 Pfizer Canada Inc., Kirkland, QC, Canada

Jacques LeLorier1 CHUM Research Center, Montréal, QC, CanadaCorrespondence[email protected]

Pages 497-503 | Published online: 06 Oct 2015

Cite this article
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

References

HoyleMFuture drug prices and cost-effectiveness analysesPharmacoeconomics200826758960218563950
PubMed Web of Science ®Google Scholar
ShihYCHanSCantorSBImpact of generic drug entry on cost-effectiveness analysisMed Decis Making2005251718015673583
PubMed Web of Science ®Google Scholar
HayJWSmeedingJCarrollNVGood research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR Drug Cost Task Force report – Part IValue Health20101313719874571
PubMed Web of Science ®Google Scholar
Guidelines for the Economic Evaluation of Health Technologies: Canada3rd EditionOttawaCanadian Agency for Drugs and Technologies in Health2006
Google Scholar
SorensenSVKansalARConnollySCost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspectiveThromb Haemost2011105590891921431243
PubMed Web of Science ®Google Scholar
Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations [webpage on the Internet]Silver Spring: US Food and Drug Administration Available from: http://www.accessdata.fda.gov/scripts/cder/ob/docs/patexclnew.cfm?Appl_No=022512&Product_No=001&table1=OB_RxAccessed October 2, 2014
Google Scholar
Register of Innovative Drugs [webpage on the Internet]OttawaHealth Canada [updated August 12, 2015]. Available from: http://www.hc-sc.gc.ca/dhp-mps/prodpharma/applic-demande/regist/reg_innov_dr-eng.phpAccessed July 8, 2015
Google Scholar
Guidance Document: Data Protection under C.08.004.1 of the Food and Drug Regulations [webpage on the Internet]OttawaHealth Canada2011 Available from: http://www.hc-sc.gc.ca/dhp-mps/prodpharma/applic-demande/guide-ld/data_donnees_protection-eng.phpAccessed July 8, 2015
Google Scholar
MoultonDProvincial squeeze on generic prices continuesCMAJ201118314E1049E105021896691
PubMed Web of Science ®Google Scholar
BeallRFNickersonJWAttaranAPan-Canadian overpricing of medicines: a 6-country study of cost control for generic medicinesOpen Med201484e130e13525426181
PubMedGoogle Scholar
The Council of the FederationProvinces and Territories Seek Significant Cost Savings for Canadians on Generic Drugs 2013 Available from: http://www.councilofthefederation.ca/phocadownload/newsroom-2013/nr-cof-generic_drugs_final-jan_18.pdfAccessed May 10, 2014
Google Scholar
LawMRMoney left on the table: generic drug prices in CanadaHealthc Policy201383172523968624
PubMedGoogle Scholar
KongYCompetition between brand-name and generics – analysis on pricing of brand-name pharmaceuticalHealth Econ200918559160618816580
PubMed Web of Science ®Google Scholar
BalabanDYDhallaIALawMRBellCMPrivate expenditures on brand name prescription drugs after generic entryAppl Health Econ Health Policy201311552352923979876
PubMedGoogle Scholar
LexchinJThe effect of generic competition on the price of brand-name drugsHealth Policy2004681475415033552
PubMed Web of Science ®Google Scholar
BellCGrillerDLawsonJLovrenDGeneric Drug Pricing and Access in Canada: What are the Implications?TorontoHealth Council of Canada2010 Available from: http://www.healthcouncilcanada.ca/rpt_det.php?id=156Accessed May 10, 2014
Google Scholar
AcostaACiapponiAAaserudMPharmaceutical policies: effects of reference pricing, other pricing, and purchasing policiesCochrane Database Syst Rev201410CD00597925318966
PubMed Web of Science ®Google Scholar
NarineLSenathirajahMSmithTEvaluating reference-based pricing: initial findings and prospectsCMAJ1999161328628810463052
PubMed Web of Science ®Google Scholar
DylstPVultoASimoensSThe impact of reference-pricing systems in Europe: a literature review and case studiesExpert Rev Pharmacoecon Outcomes Res201111672973722098289
PubMed Web of Science ®Google Scholar
KesselheimASMisonoASLeeJLClinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysisJAMA2008300212514252619050195
PubMed Web of Science ®Google Scholar
BaumgärtelCMyths, questions, facts about generic drugs in the EUGaBI J2012113438
Google Scholar
DuerdenMGHughesDAGeneric and therapeutic substitutions in the UK: are they a good thing?Br J Clin Pharmacol201070333534120716231
PubMed Web of Science ®Google Scholar
SimoensSBiosimilar medicines and cost-effectivenessClinicoecon Outcomes Res20113293621935330
PubMedGoogle Scholar
StewartAAubreyPBelseyJAddressing the health technology assessment of biosimilar pharmaceuticalsCurr Med Res Opin20102692119212620649394
PubMed Web of Science ®Google Scholar
KesselheimASStedmanMRBubrickEJSeizure outcomes following the use of generic versus brand-name antiepileptic drugs: a systematic review and meta-analysisDrugs201070560562120329806
PubMed Web of Science ®Google Scholar
MintzerSBrand spanking? The presumptive risks of generic anti-epileptic drugsEpilepsy Curr2011112545521852877
PubMed Web of Science ®Google Scholar

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Bias within economic evaluations – the impact of considering the future entry of lower-cost generics on currently estimated incremental cost-effectiveness ratios of a new drug

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Bias within economic evaluations – the impact of considering the future entry of lower-cost generics on currently estimated incremental cost-effectiveness ratios of a new drug

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date